nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—ABCB11—Vinblastine—head and neck cancer	0.471	0.726	CbGbCtD
Bosentan—CYP2C9—Fluorouracil—head and neck cancer	0.0898	0.138	CbGbCtD
Bosentan—CYP3A4—Vinblastine—head and neck cancer	0.0484	0.0745	CbGbCtD
Bosentan—CYP3A4—Docetaxel—head and neck cancer	0.0399	0.0614	CbGbCtD
Bosentan—Oligospermia—Hydroxyurea—head and neck cancer	0.013	0.0488	CcSEcCtD
Bosentan—Azoospermia—Hydroxyurea—head and neck cancer	0.0102	0.038	CcSEcCtD
Bosentan—Pain in jaw—Vinblastine—head and neck cancer	0.0092	0.0344	CcSEcCtD
Bosentan—Edema of lower extremities—Docetaxel—head and neck cancer	0.00708	0.0265	CcSEcCtD
Bosentan—Electrocardiogram change—Fluorouracil—head and neck cancer	0.00689	0.0258	CcSEcCtD
Bosentan—Lower respiratory tract infection—Docetaxel—head and neck cancer	0.00416	0.0156	CcSEcCtD
Bosentan—Skin ulcer—Hydroxyurea—head and neck cancer	0.00351	0.0131	CcSEcCtD
Bosentan—Rectal haemorrhage—Vinblastine—head and neck cancer	0.00332	0.0124	CcSEcCtD
Bosentan—ABCB11—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00325	0.0388	CbGpPWpGaD
Bosentan—EDNRA—EGFR-dependent Endothelin signaling events—EGFR—head and neck cancer	0.00315	0.0376	CbGpPWpGaD
Bosentan—Ascites—Docetaxel—head and neck cancer	0.00313	0.0117	CcSEcCtD
Bosentan—Duodenal ulcer—Docetaxel—head and neck cancer	0.00294	0.011	CcSEcCtD
Bosentan—Photophobia—Vinblastine—head and neck cancer	0.00282	0.0105	CcSEcCtD
Bosentan—EDNRA—EGFR-dependent Endothelin signaling events—HRAS—head and neck cancer	0.00253	0.0302	CbGpPWpGaD
Bosentan—Pulmonary oedema—Hydroxyurea—head and neck cancer	0.00243	0.00911	CcSEcCtD
Bosentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—head and neck cancer	0.00237	0.0283	CbGpPWpGaD
Bosentan—EDNRB—G alpha (q) signalling events—KISS1—head and neck cancer	0.00232	0.0276	CbGpPWpGaD
Bosentan—Eye irritation—Fluorouracil—head and neck cancer	0.0023	0.00863	CcSEcCtD
Bosentan—EDNRB—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.00229	0.0273	CbGpPWpGaD
Bosentan—Cerebrovascular accident—Vinblastine—head and neck cancer	0.00222	0.00831	CcSEcCtD
Bosentan—Hepatic failure—Hydroxyurea—head and neck cancer	0.00221	0.00827	CcSEcCtD
Bosentan—Intestinal obstruction—Docetaxel—head and neck cancer	0.00208	0.0078	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.00207	0.0247	CbGpPWpGaD
Bosentan—Haemoglobin decreased—Docetaxel—head and neck cancer	0.00206	0.00772	CcSEcCtD
Bosentan—EDNRB—G alpha (q) signalling events—GRP—head and neck cancer	0.00191	0.0228	CbGpPWpGaD
Bosentan—EDNRB—Peptide ligand-binding receptors—GRP—head and neck cancer	0.00188	0.0225	CbGpPWpGaD
Bosentan—Photophobia—Fluorouracil—head and neck cancer	0.00185	0.00692	CcSEcCtD
Bosentan—Angina pectoris—Vinblastine—head and neck cancer	0.00183	0.00686	CcSEcCtD
Bosentan—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.00177	0.0211	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.00171	0.0203	CbGpPWpGaD
Bosentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—head and neck cancer	0.0017	0.0202	CbGpPWpGaD
Bosentan—Eye irritation—Docetaxel—head and neck cancer	0.00166	0.00623	CcSEcCtD
Bosentan—EDNRA—G alpha (q) signalling events—KISS1—head and neck cancer	0.00166	0.0198	CbGpPWpGaD
Bosentan—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00165	0.00619	CcSEcCtD
Bosentan—Myocardial infarction—Vinblastine—head and neck cancer	0.00164	0.00615	CcSEcCtD
Bosentan—EDNRA—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.00164	0.0195	CbGpPWpGaD
Bosentan—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.00161	0.0192	CbGpPWpGaD
Bosentan—Neutropenia—Hydroxyurea—head and neck cancer	0.0016	0.006	CcSEcCtD
Bosentan—Dysuria—Hydroxyurea—head and neck cancer	0.0016	0.006	CcSEcCtD
Bosentan—Bone disorder—Docetaxel—head and neck cancer	0.00157	0.00589	CcSEcCtD
Bosentan—Weight increased—Hydroxyurea—head and neck cancer	0.00156	0.00584	CcSEcCtD
Bosentan—EDNRB—Endothelin Pathways—MAPK1—head and neck cancer	0.00156	0.0186	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00154	0.0183	CbGpPWpGaD
Bosentan—Infestation—Hydroxyurea—head and neck cancer	0.00153	0.00572	CcSEcCtD
Bosentan—Infestation NOS—Hydroxyurea—head and neck cancer	0.00153	0.00572	CcSEcCtD
Bosentan—Haemoglobin—Vinblastine—head and neck cancer	0.00151	0.00566	CcSEcCtD
Bosentan—Haemorrhage—Vinblastine—head and neck cancer	0.00151	0.00563	CcSEcCtD
Bosentan—Blood bilirubin increased—Docetaxel—head and neck cancer	0.0015	0.00562	CcSEcCtD
Bosentan—Hypoaesthesia—Vinblastine—head and neck cancer	0.0015	0.00561	CcSEcCtD
Bosentan—Stomatitis—Hydroxyurea—head and neck cancer	0.00149	0.00558	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.00148	0.0177	CbGpPWpGaD
Bosentan—Cardiac failure—Fluorouracil—head and neck cancer	0.00146	0.00548	CcSEcCtD
Bosentan—Lethargy—Fluorouracil—head and neck cancer	0.00146	0.00546	CcSEcCtD
Bosentan—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00145	0.00541	CcSEcCtD
Bosentan—Respiratory failure—Docetaxel—head and neck cancer	0.00145	0.00541	CcSEcCtD
Bosentan—Haemoglobin—Hydroxyurea—head and neck cancer	0.00138	0.00516	CcSEcCtD
Bosentan—Influenza like illness—Docetaxel—head and neck cancer	0.00138	0.00516	CcSEcCtD
Bosentan—Haemorrhage—Hydroxyurea—head and neck cancer	0.00137	0.00514	CcSEcCtD
Bosentan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.00137	0.0163	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—GRP—head and neck cancer	0.00137	0.0163	CbGpPWpGaD
Bosentan—Irritability—Fluorouracil—head and neck cancer	0.00136	0.0051	CcSEcCtD
Bosentan—Cardiac arrest—Fluorouracil—head and neck cancer	0.00136	0.00508	CcSEcCtD
Bosentan—EDNRA—Peptide ligand-binding receptors—GRP—head and neck cancer	0.00135	0.0161	CbGpPWpGaD
Bosentan—Fluid retention—Docetaxel—head and neck cancer	0.00135	0.00505	CcSEcCtD
Bosentan—Dry skin—Fluorouracil—head and neck cancer	0.00131	0.0049	CcSEcCtD
Bosentan—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00128	0.00478	CcSEcCtD
Bosentan—Pulmonary oedema—Docetaxel—head and neck cancer	0.00126	0.00473	CcSEcCtD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00126	0.0151	CbGpPWpGaD
Bosentan—Angiopathy—Hydroxyurea—head and neck cancer	0.00125	0.00466	CcSEcCtD
Bosentan—Chills—Hydroxyurea—head and neck cancer	0.00123	0.00461	CcSEcCtD
Bosentan—Eosinophilia—Fluorouracil—head and neck cancer	0.00122	0.00458	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.00122	0.0146	CbGpPWpGaD
Bosentan—Anaemia—Vinblastine—head and neck cancer	0.00121	0.00453	CcSEcCtD
Bosentan—Angina pectoris—Fluorouracil—head and neck cancer	0.0012	0.0045	CcSEcCtD
Bosentan—Erythema—Hydroxyurea—head and neck cancer	0.0012	0.00447	CcSEcCtD
Bosentan—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00119	0.00444	CcSEcCtD
Bosentan—Vertigo—Vinblastine—head and neck cancer	0.00118	0.00441	CcSEcCtD
Bosentan—Leukopenia—Vinblastine—head and neck cancer	0.00117	0.00439	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—KISS1—head and neck cancer	0.00117	0.0139	CbGpPWpGaD
Bosentan—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00115	0.00429	CcSEcCtD
Bosentan—Hepatic failure—Docetaxel—head and neck cancer	0.00115	0.00429	CcSEcCtD
Bosentan—EDNRA—Endothelin Pathways—MAPK1—head and neck cancer	0.00112	0.0133	CbGpPWpGaD
Bosentan—Pneumonia—Fluorouracil—head and neck cancer	0.00111	0.00414	CcSEcCtD
Bosentan—Anaemia—Hydroxyurea—head and neck cancer	0.0011	0.00413	CcSEcCtD
Bosentan—Discomfort—Vinblastine—head and neck cancer	0.0011	0.00413	CcSEcCtD
Bosentan—Infestation—Fluorouracil—head and neck cancer	0.0011	0.00412	CcSEcCtD
Bosentan—Infestation NOS—Fluorouracil—head and neck cancer	0.0011	0.00412	CcSEcCtD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.0011	0.0131	CbGpPWpGaD
Bosentan—Atrial fibrillation—Docetaxel—head and neck cancer	0.00109	0.00407	CcSEcCtD
Bosentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00109	0.0129	CbGpPWpGaD
Bosentan—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00109	0.00406	CcSEcCtD
Bosentan—Renal impairment—Docetaxel—head and neck cancer	0.00108	0.00405	CcSEcCtD
Bosentan—Myocardial infarction—Fluorouracil—head and neck cancer	0.00108	0.00404	CcSEcCtD
Bosentan—Stomatitis—Fluorouracil—head and neck cancer	0.00107	0.00402	CcSEcCtD
Bosentan—Conjunctivitis—Fluorouracil—head and neck cancer	0.00107	0.004	CcSEcCtD
Bosentan—Urinary tract infection—Fluorouracil—head and neck cancer	0.00107	0.004	CcSEcCtD
Bosentan—Leukopenia—Hydroxyurea—head and neck cancer	0.00107	0.004	CcSEcCtD
Bosentan—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.00106	0.0127	CbGpPWpGaD
Bosentan—Cardiac failure—Docetaxel—head and neck cancer	0.00106	0.00395	CcSEcCtD
Bosentan—Lethargy—Docetaxel—head and neck cancer	0.00105	0.00394	CcSEcCtD
Bosentan—Thrombocytopenia—Vinblastine—head and neck cancer	0.00105	0.00392	CcSEcCtD
Bosentan—Epistaxis—Fluorouracil—head and neck cancer	0.00104	0.00389	CcSEcCtD
Bosentan—Hyponatraemia—Docetaxel—head and neck cancer	0.00104	0.00387	CcSEcCtD
Bosentan—Sinusitis—Fluorouracil—head and neck cancer	0.00103	0.00387	CcSEcCtD
Bosentan—Pain in extremity—Docetaxel—head and neck cancer	0.00103	0.00386	CcSEcCtD
Bosentan—Anorexia—Vinblastine—head and neck cancer	0.00102	0.00382	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00101	0.00378	CcSEcCtD
Bosentan—Discomfort—Hydroxyurea—head and neck cancer	0.00101	0.00376	CcSEcCtD
Bosentan—Haemoglobin—Fluorouracil—head and neck cancer	0.000993	0.00372	CcSEcCtD
Bosentan—Haemorrhage—Fluorouracil—head and neck cancer	0.000988	0.0037	CcSEcCtD
Bosentan—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000983	0.00368	CcSEcCtD
Bosentan—EDNRB—Endothelins—MAPK3—head and neck cancer	0.000977	0.0116	CbGpPWpGaD
Bosentan—Oedema—Hydroxyurea—head and neck cancer	0.000976	0.00365	CcSEcCtD
Bosentan—Infection—Hydroxyurea—head and neck cancer	0.000969	0.00363	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—GRP—head and neck cancer	0.000963	0.0115	CbGpPWpGaD
Bosentan—Paraesthesia—Vinblastine—head and neck cancer	0.000961	0.00359	CcSEcCtD
Bosentan—Dehydration—Docetaxel—head and neck cancer	0.000959	0.00359	CcSEcCtD
Bosentan—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000957	0.00358	CcSEcCtD
Bosentan—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000955	0.00357	CcSEcCtD
Bosentan—Liver function test abnormal—Docetaxel—head and neck cancer	0.000952	0.00356	CcSEcCtD
Bosentan—Skin disorder—Hydroxyurea—head and neck cancer	0.000948	0.00355	CcSEcCtD
Bosentan—Dry skin—Docetaxel—head and neck cancer	0.000945	0.00354	CcSEcCtD
Bosentan—Abdominal pain upper—Docetaxel—head and neck cancer	0.000942	0.00352	CcSEcCtD
Bosentan—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000942	0.00352	CcSEcCtD
Bosentan—Anorexia—Hydroxyurea—head and neck cancer	0.00093	0.00348	CcSEcCtD
Bosentan—Decreased appetite—Vinblastine—head and neck cancer	0.00093	0.00348	CcSEcCtD
Bosentan—EDNRB—Endothelins—MAPK1—head and neck cancer	0.000929	0.0111	CbGpPWpGaD
Bosentan—Cramp muscle—Docetaxel—head and neck cancer	0.000929	0.00347	CcSEcCtD
Bosentan—Nasopharyngitis—Docetaxel—head and neck cancer	0.000922	0.00345	CcSEcCtD
Bosentan—Constipation—Vinblastine—head and neck cancer	0.000915	0.00342	CcSEcCtD
Bosentan—Pain—Vinblastine—head and neck cancer	0.000915	0.00342	CcSEcCtD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.000905	0.0108	CbGpPWpGaD
Bosentan—Bronchospasm—Docetaxel—head and neck cancer	0.000877	0.00328	CcSEcCtD
Bosentan—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000875	0.00327	CcSEcCtD
Bosentan—Dyspnoea—Hydroxyurea—head and neck cancer	0.00087	0.00325	CcSEcCtD
Bosentan—Angina pectoris—Docetaxel—head and neck cancer	0.000868	0.00325	CcSEcCtD
Bosentan—Somnolence—Hydroxyurea—head and neck cancer	0.000867	0.00325	CcSEcCtD
Bosentan—Erythema—Fluorouracil—head and neck cancer	0.00086	0.00322	CcSEcCtD
Bosentan—Dyspepsia—Hydroxyurea—head and neck cancer	0.000859	0.00321	CcSEcCtD
Bosentan—CYP2C9—Xenobiotics—CYP1A1—head and neck cancer	0.00085	0.0101	CbGpPWpGaD
Bosentan—Decreased appetite—Hydroxyurea—head and neck cancer	0.000848	0.00317	CcSEcCtD
Bosentan—Abdominal pain—Vinblastine—head and neck cancer	0.000846	0.00316	CcSEcCtD
Bosentan—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000842	0.00315	CcSEcCtD
Bosentan—Fatigue—Hydroxyurea—head and neck cancer	0.000841	0.00315	CcSEcCtD
Bosentan—EDNRA—GPCR ligand binding—KISS1—head and neck cancer	0.000837	0.00997	CbGpPWpGaD
Bosentan—Pain—Hydroxyurea—head and neck cancer	0.000834	0.00312	CcSEcCtD
Bosentan—Constipation—Hydroxyurea—head and neck cancer	0.000834	0.00312	CcSEcCtD
Bosentan—Neutropenia—Docetaxel—head and neck cancer	0.000833	0.00312	CcSEcCtD
Bosentan—CYP2C9—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000817	0.00974	CbGpPWpGaD
Bosentan—Weight increased—Docetaxel—head and neck cancer	0.000811	0.00304	CcSEcCtD
Bosentan—Vision blurred—Fluorouracil—head and neck cancer	0.000811	0.00303	CcSEcCtD
Bosentan—Weight decreased—Docetaxel—head and neck cancer	0.000806	0.00302	CcSEcCtD
Bosentan—Pneumonia—Docetaxel—head and neck cancer	0.000799	0.00299	CcSEcCtD
Bosentan—Anaemia—Fluorouracil—head and neck cancer	0.000795	0.00298	CcSEcCtD
Bosentan—Infestation—Docetaxel—head and neck cancer	0.000795	0.00297	CcSEcCtD
Bosentan—Infestation NOS—Docetaxel—head and neck cancer	0.000795	0.00297	CcSEcCtD
Bosentan—Hypersensitivity—Vinblastine—head and neck cancer	0.000788	0.00295	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000788	0.00295	CcSEcCtD
Bosentan—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000783	0.00293	CcSEcCtD
Bosentan—Renal failure—Docetaxel—head and neck cancer	0.000781	0.00292	CcSEcCtD
Bosentan—Myocardial infarction—Docetaxel—head and neck cancer	0.000779	0.00292	CcSEcCtD
Bosentan—Stomatitis—Docetaxel—head and neck cancer	0.000775	0.0029	CcSEcCtD
Bosentan—Jaundice—Docetaxel—head and neck cancer	0.000775	0.0029	CcSEcCtD
Bosentan—Conjunctivitis—Docetaxel—head and neck cancer	0.000772	0.00289	CcSEcCtD
Bosentan—Body temperature increased—Hydroxyurea—head and neck cancer	0.000771	0.00289	CcSEcCtD
Bosentan—Leukopenia—Fluorouracil—head and neck cancer	0.00077	0.00288	CcSEcCtD
Bosentan—Asthenia—Vinblastine—head and neck cancer	0.000768	0.00287	CcSEcCtD
Bosentan—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000752	0.00281	CcSEcCtD
Bosentan—Epistaxis—Docetaxel—head and neck cancer	0.00075	0.0028	CcSEcCtD
Bosentan—EDNRB—Endothelins—HRAS—head and neck cancer	0.000746	0.00889	CbGpPWpGaD
Bosentan—Chest pain—Fluorouracil—head and neck cancer	0.000733	0.00274	CcSEcCtD
Bosentan—Diarrhoea—Vinblastine—head and neck cancer	0.000732	0.00274	CcSEcCtD
Bosentan—Discomfort—Fluorouracil—head and neck cancer	0.000724	0.00271	CcSEcCtD
Bosentan—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000719	0.00269	CcSEcCtD
Bosentan—Haemoglobin—Docetaxel—head and neck cancer	0.000717	0.00268	CcSEcCtD
Bosentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000716	0.00853	CbGpPWpGaD
Bosentan—Haemorrhage—Docetaxel—head and neck cancer	0.000713	0.00267	CcSEcCtD
Bosentan—Hepatitis—Docetaxel—head and neck cancer	0.000713	0.00267	CcSEcCtD
Bosentan—Hypoaesthesia—Docetaxel—head and neck cancer	0.00071	0.00266	CcSEcCtD
Bosentan—Dizziness—Vinblastine—head and neck cancer	0.000707	0.00265	CcSEcCtD
Bosentan—Urinary tract disorder—Docetaxel—head and neck cancer	0.000705	0.00264	CcSEcCtD
Bosentan—Oedema peripheral—Docetaxel—head and neck cancer	0.000703	0.00263	CcSEcCtD
Bosentan—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000702	0.00263	CcSEcCtD
Bosentan—Oedema—Fluorouracil—head and neck cancer	0.000702	0.00263	CcSEcCtD
Bosentan—Asthenia—Hydroxyurea—head and neck cancer	0.0007	0.00262	CcSEcCtD
Bosentan—Urethral disorder—Docetaxel—head and neck cancer	0.000699	0.00262	CcSEcCtD
Bosentan—EDNRA—Endothelins—MAPK3—head and neck cancer	0.000699	0.00833	CbGpPWpGaD
Bosentan—Infection—Fluorouracil—head and neck cancer	0.000698	0.00261	CcSEcCtD
Bosentan—EDNRA—GPCR ligand binding—GRP—head and neck cancer	0.000689	0.00821	CbGpPWpGaD
Bosentan—Nervous system disorder—Fluorouracil—head and neck cancer	0.000689	0.00258	CcSEcCtD
Bosentan—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000688	0.00257	CcSEcCtD
Bosentan—Tachycardia—Fluorouracil—head and neck cancer	0.000685	0.00256	CcSEcCtD
Bosentan—Vomiting—Vinblastine—head and neck cancer	0.00068	0.00255	CcSEcCtD
Bosentan—Erythema multiforme—Docetaxel—head and neck cancer	0.000675	0.00252	CcSEcCtD
Bosentan—Headache—Vinblastine—head and neck cancer	0.00067	0.00251	CcSEcCtD
Bosentan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.00067	0.00798	CbGpPWpGaD
Bosentan—Anorexia—Fluorouracil—head and neck cancer	0.000669	0.0025	CcSEcCtD
Bosentan—Diarrhoea—Hydroxyurea—head and neck cancer	0.000667	0.0025	CcSEcCtD
Bosentan—Eye disorder—Docetaxel—head and neck cancer	0.000667	0.00249	CcSEcCtD
Bosentan—EDNRA—Endothelins—MAPK1—head and neck cancer	0.000665	0.00793	CbGpPWpGaD
Bosentan—Flushing—Docetaxel—head and neck cancer	0.000662	0.00248	CcSEcCtD
Bosentan—Cardiac disorder—Docetaxel—head and neck cancer	0.000662	0.00248	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—KISS1—head and neck cancer	0.000661	0.00787	CbGpPWpGaD
Bosentan—EDNRB—Endothelins—AKT1—head and neck cancer	0.000659	0.00785	CbGpPWpGaD
Bosentan—Hypotension—Fluorouracil—head and neck cancer	0.000656	0.00246	CcSEcCtD
Bosentan—Angiopathy—Docetaxel—head and neck cancer	0.000647	0.00242	CcSEcCtD
Bosentan—Dizziness—Hydroxyurea—head and neck cancer	0.000645	0.00241	CcSEcCtD
Bosentan—Immune system disorder—Docetaxel—head and neck cancer	0.000644	0.00241	CcSEcCtD
Bosentan—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.000643	0.00766	CbGpPWpGaD
Bosentan—Mediastinal disorder—Docetaxel—head and neck cancer	0.000643	0.00241	CcSEcCtD
Bosentan—Chills—Docetaxel—head and neck cancer	0.00064	0.0024	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00064	0.00239	CcSEcCtD
Bosentan—Nausea—Vinblastine—head and neck cancer	0.000635	0.00238	CcSEcCtD
Bosentan—Insomnia—Fluorouracil—head and neck cancer	0.000635	0.00238	CcSEcCtD
Bosentan—Paraesthesia—Fluorouracil—head and neck cancer	0.000631	0.00236	CcSEcCtD
Bosentan—Dyspnoea—Fluorouracil—head and neck cancer	0.000626	0.00234	CcSEcCtD
Bosentan—Mental disorder—Docetaxel—head and neck cancer	0.000625	0.00234	CcSEcCtD
Bosentan—Somnolence—Fluorouracil—head and neck cancer	0.000624	0.00234	CcSEcCtD
Bosentan—Malnutrition—Docetaxel—head and neck cancer	0.000621	0.00232	CcSEcCtD
Bosentan—Erythema—Docetaxel—head and neck cancer	0.000621	0.00232	CcSEcCtD
Bosentan—Vomiting—Hydroxyurea—head and neck cancer	0.00062	0.00232	CcSEcCtD
Bosentan—Dyspepsia—Fluorouracil—head and neck cancer	0.000618	0.00231	CcSEcCtD
Bosentan—Rash—Hydroxyurea—head and neck cancer	0.000615	0.0023	CcSEcCtD
Bosentan—Dermatitis—Hydroxyurea—head and neck cancer	0.000615	0.0023	CcSEcCtD
Bosentan—Headache—Hydroxyurea—head and neck cancer	0.000611	0.00229	CcSEcCtD
Bosentan—Decreased appetite—Fluorouracil—head and neck cancer	0.00061	0.00228	CcSEcCtD
Bosentan—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.00061	0.00727	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000606	0.00227	CcSEcCtD
Bosentan—Back pain—Docetaxel—head and neck cancer	0.000601	0.00225	CcSEcCtD
Bosentan—Pain—Fluorouracil—head and neck cancer	0.0006	0.00225	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—KISS1—head and neck cancer	0.0006	0.00715	CbGpPWpGaD
Bosentan—Muscle spasms—Docetaxel—head and neck cancer	0.000597	0.00223	CcSEcCtD
Bosentan—Nausea—Hydroxyurea—head and neck cancer	0.000579	0.00217	CcSEcCtD
Bosentan—Anaemia—Docetaxel—head and neck cancer	0.000574	0.00215	CcSEcCtD
Bosentan—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.00056	0.00668	CbGpPWpGaD
Bosentan—Urticaria—Fluorouracil—head and neck cancer	0.000558	0.00209	CcSEcCtD
Bosentan—Syncope—Docetaxel—head and neck cancer	0.000557	0.00208	CcSEcCtD
Bosentan—Leukopenia—Docetaxel—head and neck cancer	0.000556	0.00208	CcSEcCtD
Bosentan—Body temperature increased—Fluorouracil—head and neck cancer	0.000555	0.00208	CcSEcCtD
Bosentan—Palpitations—Docetaxel—head and neck cancer	0.000549	0.00205	CcSEcCtD
Bosentan—Loss of consciousness—Docetaxel—head and neck cancer	0.000546	0.00204	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—GRP—head and neck cancer	0.000544	0.00648	CbGpPWpGaD
Bosentan—Cough—Docetaxel—head and neck cancer	0.000542	0.00203	CcSEcCtD
Bosentan—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000539	0.00642	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—HRAS—head and neck cancer	0.000534	0.00636	CbGpPWpGaD
Bosentan—Chest pain—Docetaxel—head and neck cancer	0.000529	0.00198	CcSEcCtD
Bosentan—Arthralgia—Docetaxel—head and neck cancer	0.000529	0.00198	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000525	0.00196	CcSEcCtD
Bosentan—Hypersensitivity—Fluorouracil—head and neck cancer	0.000517	0.00194	CcSEcCtD
Bosentan—Dry mouth—Docetaxel—head and neck cancer	0.000517	0.00193	CcSEcCtD
Bosentan—Oedema—Docetaxel—head and neck cancer	0.000507	0.0019	CcSEcCtD
Bosentan—Anaphylactic shock—Docetaxel—head and neck cancer	0.000507	0.0019	CcSEcCtD
Bosentan—Infection—Docetaxel—head and neck cancer	0.000504	0.00188	CcSEcCtD
Bosentan—Shock—Docetaxel—head and neck cancer	0.000499	0.00187	CcSEcCtD
Bosentan—Nervous system disorder—Docetaxel—head and neck cancer	0.000497	0.00186	CcSEcCtD
Bosentan—Pruritus—Fluorouracil—head and neck cancer	0.000497	0.00186	CcSEcCtD
Bosentan—Thrombocytopenia—Docetaxel—head and neck cancer	0.000496	0.00186	CcSEcCtD
Bosentan—Tachycardia—Docetaxel—head and neck cancer	0.000495	0.00185	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—GRP—head and neck cancer	0.000494	0.00589	CbGpPWpGaD
Bosentan—Skin disorder—Docetaxel—head and neck cancer	0.000492	0.00184	CcSEcCtD
Bosentan—Anorexia—Docetaxel—head and neck cancer	0.000483	0.00181	CcSEcCtD
Bosentan—Diarrhoea—Fluorouracil—head and neck cancer	0.00048	0.0018	CcSEcCtD
Bosentan—Hypotension—Docetaxel—head and neck cancer	0.000474	0.00177	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—KISS1—head and neck cancer	0.000473	0.00564	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—AKT1—head and neck cancer	0.000471	0.00562	CbGpPWpGaD
Bosentan—Dizziness—Fluorouracil—head and neck cancer	0.000464	0.00174	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000462	0.00173	CcSEcCtD
Bosentan—Insomnia—Docetaxel—head and neck cancer	0.000458	0.00172	CcSEcCtD
Bosentan—Paraesthesia—Docetaxel—head and neck cancer	0.000455	0.0017	CcSEcCtD
Bosentan—Dyspnoea—Docetaxel—head and neck cancer	0.000452	0.00169	CcSEcCtD
Bosentan—Somnolence—Docetaxel—head and neck cancer	0.000451	0.00169	CcSEcCtD
Bosentan—Vomiting—Fluorouracil—head and neck cancer	0.000446	0.00167	CcSEcCtD
Bosentan—Dyspepsia—Docetaxel—head and neck cancer	0.000446	0.00167	CcSEcCtD
Bosentan—Rash—Fluorouracil—head and neck cancer	0.000443	0.00166	CcSEcCtD
Bosentan—Dermatitis—Fluorouracil—head and neck cancer	0.000442	0.00166	CcSEcCtD
Bosentan—Decreased appetite—Docetaxel—head and neck cancer	0.000441	0.00165	CcSEcCtD
Bosentan—Headache—Fluorouracil—head and neck cancer	0.00044	0.00165	CcSEcCtD
Bosentan—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000438	0.00164	CcSEcCtD
Bosentan—Fatigue—Docetaxel—head and neck cancer	0.000437	0.00164	CcSEcCtD
Bosentan—Pain—Docetaxel—head and neck cancer	0.000433	0.00162	CcSEcCtD
Bosentan—Constipation—Docetaxel—head and neck cancer	0.000433	0.00162	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—KISS1—head and neck cancer	0.000429	0.00512	CbGpPWpGaD
Bosentan—Nausea—Fluorouracil—head and neck cancer	0.000417	0.00156	CcSEcCtD
Bosentan—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000414	0.00155	CcSEcCtD
Bosentan—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000412	0.00491	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000408	0.00487	CbGpPWpGaD
Bosentan—Abdominal pain—Docetaxel—head and neck cancer	0.000401	0.0015	CcSEcCtD
Bosentan—Body temperature increased—Docetaxel—head and neck cancer	0.000401	0.0015	CcSEcCtD
Bosentan—ABCB11—Metabolism—UROD—head and neck cancer	0.0004	0.00477	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—GRP—head and neck cancer	0.000389	0.00464	CbGpPWpGaD
Bosentan—Hypersensitivity—Docetaxel—head and neck cancer	0.000373	0.0014	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	0.000366	0.00436	CbGpPWpGaD
Bosentan—Asthenia—Docetaxel—head and neck cancer	0.000364	0.00136	CcSEcCtD
Bosentan—Pruritus—Docetaxel—head and neck cancer	0.000359	0.00134	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—KISS1—head and neck cancer	0.000354	0.00422	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—GRP—head and neck cancer	0.000354	0.00421	CbGpPWpGaD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000353	0.00421	CbGpPWpGaD
Bosentan—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000348	0.00415	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	0.000348	0.00415	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	0.000348	0.00415	CbGpPWpGaD
Bosentan—Diarrhoea—Docetaxel—head and neck cancer	0.000347	0.0013	CcSEcCtD
Bosentan—EDNRB—G alpha (q) signalling events—PIK3CA—head and neck cancer	0.000338	0.00402	CbGpPWpGaD
Bosentan—Dizziness—Docetaxel—head and neck cancer	0.000335	0.00125	CcSEcCtD
Bosentan—CYP2C9—Biological oxidations—NAT2—head and neck cancer	0.000324	0.00387	CbGpPWpGaD
Bosentan—Vomiting—Docetaxel—head and neck cancer	0.000322	0.00121	CcSEcCtD
Bosentan—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	0.00032	0.00381	CbGpPWpGaD
Bosentan—Rash—Docetaxel—head and neck cancer	0.00032	0.0012	CcSEcCtD
Bosentan—Dermatitis—Docetaxel—head and neck cancer	0.000319	0.00119	CcSEcCtD
Bosentan—Headache—Docetaxel—head and neck cancer	0.000318	0.00119	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000311	0.0037	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.000302	0.0036	CbGpPWpGaD
Bosentan—Nausea—Docetaxel—head and neck cancer	0.000301	0.00113	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—GRP—head and neck cancer	0.000292	0.00348	CbGpPWpGaD
Bosentan—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000288	0.00343	CbGpPWpGaD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000286	0.00341	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—STAT6—head and neck cancer	0.000283	0.00338	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.000279	0.00333	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	0.000262	0.00312	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KISS1—head and neck cancer	0.000254	0.00302	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—YAP1—head and neck cancer	0.000251	0.00299	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	0.000249	0.00297	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	0.000249	0.00297	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000243	0.00289	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—PIK3CA—head and neck cancer	0.000242	0.00288	CbGpPWpGaD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000233	0.00277	CbGpPWpGaD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00023	0.00274	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.000216	0.00258	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.000214	0.00255	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.000211	0.00252	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—GRP—head and neck cancer	0.000209	0.00249	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—STAT6—head and neck cancer	0.000203	0.00242	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.0002	0.00238	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000189	0.00225	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—YAP1—head and neck cancer	0.000179	0.00214	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000177	0.0021	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000175	0.00208	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—NAT2—head and neck cancer	0.000166	0.00198	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	0.00016	0.00191	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	0.000158	0.00188	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	0.000152	0.00181	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	0.00015	0.00179	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—DPYD—head and neck cancer	0.000146	0.00174	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—IL2—head and neck cancer	0.000145	0.00173	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—YAP1—head and neck cancer	0.000138	0.00165	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—UROD—head and neck cancer	0.000134	0.00159	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—IL2—head and neck cancer	0.000132	0.00157	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NOTCH1—head and neck cancer	0.000113	0.00135	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—MAPK3—head and neck cancer	0.000106	0.00126	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	0.000106	0.00126	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	0.000104	0.00124	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000104	0.00124	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—IL2—head and neck cancer	0.000104	0.00124	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000104	0.00124	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—MAPK1—head and neck cancer	0.000101	0.0012	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—EGFR—head and neck cancer	0.000101	0.0012	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	0.0001	0.00119	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	9.88e-05	0.00118	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CA—head and neck cancer	9.62e-05	0.00115	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL2—head and neck cancer	9.42e-05	0.00112	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	9.06e-05	0.00108	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—UROD—head and neck cancer	8.81e-05	0.00105	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PIK3CA—head and neck cancer	8.74e-05	0.00104	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—TYMS—head and neck cancer	8.3e-05	0.00099	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTM1—head and neck cancer	8.21e-05	0.000978	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NOTCH1—head and neck cancer	8.09e-05	0.000964	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—HRAS—head and neck cancer	8.09e-05	0.000964	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—AKT1—head and neck cancer	7.86e-05	0.000937	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GPX1—head and neck cancer	7.86e-05	0.000937	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP1A1—head and neck cancer	7.78e-05	0.000928	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL2—head and neck cancer	7.78e-05	0.000927	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCND1—head and neck cancer	7.58e-05	0.000904	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—MAPK3—head and neck cancer	7.58e-05	0.000903	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTEN—head and neck cancer	7.32e-05	0.000872	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—MAPK1—head and neck cancer	7.21e-05	0.000859	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—EGFR—head and neck cancer	7.21e-05	0.000859	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—AKT1—head and neck cancer	7.14e-05	0.000851	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CA—head and neck cancer	6.89e-05	0.000821	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—VEGFA—head and neck cancer	6.61e-05	0.000788	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—STAT3—head and neck cancer	6.54e-05	0.00078	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	6.39e-05	0.000762	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CA—head and neck cancer	6.25e-05	0.000745	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MAPK3—head and neck cancer	6.25e-05	0.000745	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MAPK1—head and neck cancer	5.95e-05	0.000709	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EGFR—head and neck cancer	5.95e-05	0.000709	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	5.89e-05	0.000702	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	5.83e-05	0.000695	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—HRAS—head and neck cancer	5.79e-05	0.00069	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AKT1—head and neck cancer	5.63e-05	0.000671	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL2—head and neck cancer	5.57e-05	0.000663	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NAT2—head and neck cancer	5.55e-05	0.000661	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCND1—head and neck cancer	5.43e-05	0.000647	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTEN—head and neck cancer	5.24e-05	0.000624	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CA—head and neck cancer	5.16e-05	0.000615	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—AKT1—head and neck cancer	5.11e-05	0.000609	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—head and neck cancer	4.99e-05	0.000595	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—DPYD—head and neck cancer	4.87e-05	0.00058	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HRAS—head and neck cancer	4.78e-05	0.000569	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—VEGFA—head and neck cancer	4.73e-05	0.000564	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—STAT3—head and neck cancer	4.68e-05	0.000558	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTGS2—head and neck cancer	4.63e-05	0.000552	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—YAP1—head and neck cancer	4.62e-05	0.00055	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MAPK3—head and neck cancer	4.47e-05	0.000533	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MAPK1—head and neck cancer	4.26e-05	0.000507	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EGFR—head and neck cancer	4.26e-05	0.000507	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKT1—head and neck cancer	4.22e-05	0.000503	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTEN—head and neck cancer	4.04e-05	0.000481	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CA—head and neck cancer	3.69e-05	0.00044	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NAT2—head and neck cancer	3.66e-05	0.000436	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—head and neck cancer	3.57e-05	0.000426	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	3.47e-05	0.000414	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HRAS—head and neck cancer	3.42e-05	0.000407	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—DPYD—head and neck cancer	3.21e-05	0.000382	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—YAP1—head and neck cancer	3.05e-05	0.000363	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	3.03e-05	0.000361	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKT1—head and neck cancer	3.02e-05	0.00036	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CA—head and neck cancer	2.85e-05	0.000339	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TYMS—head and neck cancer	2.77e-05	0.00033	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTM1—head and neck cancer	2.74e-05	0.000327	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GPX1—head and neck cancer	2.62e-05	0.000313	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP1A1—head and neck cancer	2.6e-05	0.00031	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AKT1—head and neck cancer	2.33e-05	0.000277	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.13e-05	0.000254	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TYMS—head and neck cancer	1.83e-05	0.000218	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.81e-05	0.000215	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GPX1—head and neck cancer	1.73e-05	0.000206	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.71e-05	0.000204	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS2—head and neck cancer	1.55e-05	0.000184	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTEN—head and neck cancer	1.35e-05	0.000161	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS2—head and neck cancer	1.02e-05	0.000121	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CA—head and neck cancer	9.51e-06	0.000113	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTEN—head and neck cancer	8.89e-06	0.000106	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKT1—head and neck cancer	7.77e-06	9.26e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CA—head and neck cancer	6.27e-06	7.47e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKT1—head and neck cancer	5.12e-06	6.1e-05	CbGpPWpGaD
